Pharmacosmos Therapeutics Inc., an affiliate of Pharmacosmos, markets Monoferric in the US high-dose IV iron market. Pharmacosmos Therapeutics brings together: - A best-in-class product - Resources required to drive rapid growth - An ability to adapt quickly to market change - A new standard for patient care Founded in 1965, Pharmacosmos headquarters in Denmark. We are a family-held company built on passionate and knowledgeable people. We value integrity, open-mindedness, and respect. These values guide us in our endeavors and touch everyone in every part of our journey. We respect everyone who becomes a part of our journey. As a company , we strive to become the world leader in the treatment of iron deficiency anemia, one of the largest global health issues, and aspire to change the way iron deficiency anemia is treated. Pharmacosmos is focused on three business areas: branded pharmaceuticals, APIs, and carbohydrates. The US company focuses primarily on the prescription iron pharmaceutical market. Two-thirds of its revenue comes from this segment of the business. Pharmaceutical grade carbohydrates and API enhance their supply chain capabilities and overall market strategy and positioning. The company takes pride in our robust research and development program with a focus on human and veterinary medicines. Pharmacosmos cultivates a collaborative, performance-based culture. We recognize and reward employees for the value they bring and empower them to do meaningful work. Built upon the heritage and financial strength of the parent company, Pharmacosmos Therapeutics benefits from a singular focus, driving the growth of Monoferric.